• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » The CenterWatch Monthly, May 2012

The CenterWatch Monthly, May 2012

May 1, 2012
CenterWatch Staff

Newer sites most optimistic about the future

Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns about the stability of the clinical research environment. The size of an individual grant for industry sponsored trials has either declined or remained flat for sites of all sizes and types, and a majority of sites in all subgroups, except for those in the largest and least experienced segments, won’t hire new staff this year…

Risk-based monitoring slow to catch on with industry

It’s estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of study budgets. Now, posited the FDA and European Medicines Agency (EMA), the industry has the technology to handle most monitoring centrally. Thus, risk-based monitoring could save the industry millions in monitoring costs. But so far the sponsor community—slow to change and also fearing the regulatory bodies may not truly mean what they say—is not leaping to adopt the new concept…

Eye on Millennium

Millennium, The Takeda Oncology Company, is a biopharmaceutical genomics company focused exclusively on oncology. Millennium discovers and develops novel treatments, applying world-class recombinant technology to a wide variety of oncology disease targets. The company’s largest commercial success to date has been Velcade (bortezomib), developed through Nobel Prize-winning protein homeostasis science and now approved in more than 87 countries for multiple myeloma and relapsed mantle cell lymphoma…

 

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing